Background CoronaVac, an inactivated whole-virion SARS-CoV-2 vaccine, has been shown to be well tolerated with a good safety profile in individuals aged 18 years and older in phase 1/2 trials, and provided a good humoral response against SARS-CoV-2. We present the interim efficacy and safety results of a phase 3 clinical trial of CoronaVac in Turkey.Methods This was a double-blind, randomised, placebo-controlled phase 3 trial. Volunteers aged 18-59 years with no history of COVID-19 and with negative PCR and antibody test results for SARS-CoV-2 were enrolled at 24 centres in Turkey. Exclusion criteria included (but were not limited to) immunosuppressive therapy (including steroids) within the past 6 months, bleeding disorders, asplenia, and receipt of any blood products or immunoglobulins within the past 3 months. The K1 cohort consisted of health-care workers (randomised in a 1:1 ratio), and individuals other than health-care workers were also recruited into the K2 cohort (randomised in a 2:1 ratio) using an interactive web response system. The study vaccine was 3 μg inactivated SARS-CoV-2 virion adsorbed to aluminium hydroxide in a 0•5 mL aqueous suspension. Participants received either vaccine or placebo (consisting of all vaccine components except inactivated virus) intramuscularly on days 0 and 14. The primary efficacy outcome was the prevention of PCR-confirmed symptomatic COVID-19 at least 14 days after the second dose in the per protocol population. Safety analyses were done in the intention-to-treat population. This study is registered with ClinicalTrials.gov (NCT04582344) and is active but no longer recruiting.

Background The determination of the acceptance of the COVID‐19 vaccine by the health personnel will also be a guide for the upcoming vaccination studies. The aim of this study is to determine the acceptance status of COVID‐19 vaccine amongst healthcare professionals. Materials and methods A total of 1138 healthcare workers participated in this cross‐sectional study between 17th and 20th of September, 2020. The questionnaire, which was delivered via social media, was filled out by the participants over "Google Forms." Results As a result of the questionnaire, 68.6% of the healthcare professionals stated that they could be vaccinated. Men, students, the younger age group, and those who had a previous flu shot were all willing to get the COVID‐19 vaccine. Conclusions Efforts to increase the knowledge of healthcare professionals about the new vaccine and to eliminate their doubts and concerns are important.